The pharmacological management of depression – Update 2017

Depression affects nearly 350 million people worldwide. Local data indicates that approximately 17% of all South Africans will experience at least one episode of depression in their lifetime. Depressive disorders contribute significantly towards overall morbidity and increased risk for suicide. Anti...

Full description

Bibliographic Details
Main Authors: Elzbieta Osuch, Andre Marais
Format: Article
Language:English
Published: AOSIS 2017-03-01
Series:South African Family Practice
Subjects:
Online Access:https://safpj.co.za/index.php/safpj/article/view/4625
id doaj-05c5d74712c144ffb5c80d8a93e6b05f
record_format Article
spelling doaj-05c5d74712c144ffb5c80d8a93e6b05f2020-11-25T02:53:10ZengAOSISSouth African Family Practice2078-61902078-62042017-03-0159161610.4102/safp.v59i1.46253703The pharmacological management of depression – Update 2017Elzbieta Osuch0Andre Marais1Sefako Makgatho Health Sciences UniversityUniversity of PretoriaDepression affects nearly 350 million people worldwide. Local data indicates that approximately 17% of all South Africans will experience at least one episode of depression in their lifetime. Depressive disorders contribute significantly towards overall morbidity and increased risk for suicide. Antidepressant therapy remains one of the cornerstones in the management of depressive disorders. Although the efficacy of antidepressive drugs is continuously subjected to criticism, thousands of controlled clinical trials have shown, and will continue to show, their benefit in the effective treatment of depressive disorders. Since the introduction of antidepressants in the early 1950s, researchers have been searching for an ideal antidepressant able to adequately reduce, preserve and prevent features of depression with the absence of side effects. This article summarizes the currently available antidepressant drugs in South Africa. Discontinued products have been omitted and newly registered agents have been added. This review does not contain reference to any experimental drug, or substances not yet available for local use.https://safpj.co.za/index.php/safpj/article/view/4625major depressive disorderantidepressantserotoninnoradrenalinedopamine
collection DOAJ
language English
format Article
sources DOAJ
author Elzbieta Osuch
Andre Marais
spellingShingle Elzbieta Osuch
Andre Marais
The pharmacological management of depression – Update 2017
South African Family Practice
major depressive disorder
antidepressant
serotonin
noradrenaline
dopamine
author_facet Elzbieta Osuch
Andre Marais
author_sort Elzbieta Osuch
title The pharmacological management of depression – Update 2017
title_short The pharmacological management of depression – Update 2017
title_full The pharmacological management of depression – Update 2017
title_fullStr The pharmacological management of depression – Update 2017
title_full_unstemmed The pharmacological management of depression – Update 2017
title_sort pharmacological management of depression – update 2017
publisher AOSIS
series South African Family Practice
issn 2078-6190
2078-6204
publishDate 2017-03-01
description Depression affects nearly 350 million people worldwide. Local data indicates that approximately 17% of all South Africans will experience at least one episode of depression in their lifetime. Depressive disorders contribute significantly towards overall morbidity and increased risk for suicide. Antidepressant therapy remains one of the cornerstones in the management of depressive disorders. Although the efficacy of antidepressive drugs is continuously subjected to criticism, thousands of controlled clinical trials have shown, and will continue to show, their benefit in the effective treatment of depressive disorders. Since the introduction of antidepressants in the early 1950s, researchers have been searching for an ideal antidepressant able to adequately reduce, preserve and prevent features of depression with the absence of side effects. This article summarizes the currently available antidepressant drugs in South Africa. Discontinued products have been omitted and newly registered agents have been added. This review does not contain reference to any experimental drug, or substances not yet available for local use.
topic major depressive disorder
antidepressant
serotonin
noradrenaline
dopamine
url https://safpj.co.za/index.php/safpj/article/view/4625
work_keys_str_mv AT elzbietaosuch thepharmacologicalmanagementofdepressionupdate2017
AT andremarais thepharmacologicalmanagementofdepressionupdate2017
AT elzbietaosuch pharmacologicalmanagementofdepressionupdate2017
AT andremarais pharmacologicalmanagementofdepressionupdate2017
_version_ 1724726279568097280